中华核医学与分子影像杂志
中華覈醫學與分子影像雜誌
중화핵의학여분자영상잡지
Chinese Journal of Nuclear Medicine and Molecular Imaging
2015年
2期
135-138
,共4页
翟士军%邱玉华%郁春景%陈永井%吴玉玉%齐晓薇%徐巧玲%万卫星
翟士軍%邱玉華%鬱春景%陳永井%吳玉玉%齊曉薇%徐巧玲%萬衛星
적사군%구옥화%욱춘경%진영정%오옥옥%제효미%서교령%만위성
淋巴瘤,B细胞%放射免疫疗法%抗体,单克隆%同位素标记%碘放射性同位素%小鼠,裸
淋巴瘤,B細胞%放射免疫療法%抗體,單剋隆%同位素標記%碘放射性同位素%小鼠,裸
림파류,B세포%방사면역요법%항체,단극륭%동위소표기%전방사성동위소%소서,라
Lymphoma,B-cell%Radioimmunotherapy%Antibodies,monoclonal%Isotope labeling%Iodine radioisotopes%Mice,nude
目的 探讨131I标记的抗CD80单克隆抗体4E5(131I-4E5)对荷人淋巴瘤裸鼠的治疗效果.方法 采用Iodogen法进行4E5的131I标记,并对131I-4E5的免疫活性及稳定性进行分析;MTT法检测131I-4E5和4E5在体外对B淋巴瘤Raji细胞的杀伤效应.经荷瘤裸鼠尾静脉注入7.4 MBq(0.2 ml)的131I-4E5,72 h后处死荷瘤裸鼠,进行体内生物分布研究,计算各脏器或组织的放射性摄取(％ID/g).将荷瘤裸鼠按随机数字表法分为3组,分别经尾静脉注射131I-4E5、4E5及生理盐水对照,观察各组肿瘤生长情况,计算给药后15 d的肿瘤生长抑制率,然后处死荷瘤裸鼠,取肿瘤组织行常规病理分析.实验数据采用单因素方差分析及两样本t检验分析.结果 131I-4E5的标记率为(78.3±2.4)％,放化纯为(95.7±1.8)％,比活度为579.4 GBq/g;131I-4E5与Raji细胞的结合率为(36.1±2.6)％;131I-4E5对Raji细胞的杀伤作用呈剂量依赖性,差异有统计学意义(F=33.882,P＜0.001),不同剂量的131I-4E5对Raji细胞的抑制率均高于4E5(t:3.986～5.515,均P＜0.05).生物分布结果显示,肿瘤组织对131I-4E5有较高的摄取能力,肿瘤/肌肉比值为6.05±1.20;与对照组比较,131I-4E5组和4E5组的肿瘤生长均减慢,其中131I-4E5的肿瘤抑制效果更为明显,给药后15d时的肿瘤抑制率为71.69％.病理结果显示2组均可见肿瘤细胞坏死,其中131I-4E5组肿瘤细胞坏死更为明显.结论 131I-4E5在荷淋巴瘤裸鼠体内具有靶向定位能力,对肿瘤生长有明显的抑制作用,具有良好的RIT效果和潜在的临床应用价值.
目的 探討131I標記的抗CD80單剋隆抗體4E5(131I-4E5)對荷人淋巴瘤裸鼠的治療效果.方法 採用Iodogen法進行4E5的131I標記,併對131I-4E5的免疫活性及穩定性進行分析;MTT法檢測131I-4E5和4E5在體外對B淋巴瘤Raji細胞的殺傷效應.經荷瘤裸鼠尾靜脈註入7.4 MBq(0.2 ml)的131I-4E5,72 h後處死荷瘤裸鼠,進行體內生物分佈研究,計算各髒器或組織的放射性攝取(％ID/g).將荷瘤裸鼠按隨機數字錶法分為3組,分彆經尾靜脈註射131I-4E5、4E5及生理鹽水對照,觀察各組腫瘤生長情況,計算給藥後15 d的腫瘤生長抑製率,然後處死荷瘤裸鼠,取腫瘤組織行常規病理分析.實驗數據採用單因素方差分析及兩樣本t檢驗分析.結果 131I-4E5的標記率為(78.3±2.4)％,放化純為(95.7±1.8)％,比活度為579.4 GBq/g;131I-4E5與Raji細胞的結閤率為(36.1±2.6)％;131I-4E5對Raji細胞的殺傷作用呈劑量依賴性,差異有統計學意義(F=33.882,P＜0.001),不同劑量的131I-4E5對Raji細胞的抑製率均高于4E5(t:3.986～5.515,均P＜0.05).生物分佈結果顯示,腫瘤組織對131I-4E5有較高的攝取能力,腫瘤/肌肉比值為6.05±1.20;與對照組比較,131I-4E5組和4E5組的腫瘤生長均減慢,其中131I-4E5的腫瘤抑製效果更為明顯,給藥後15d時的腫瘤抑製率為71.69％.病理結果顯示2組均可見腫瘤細胞壞死,其中131I-4E5組腫瘤細胞壞死更為明顯.結論 131I-4E5在荷淋巴瘤裸鼠體內具有靶嚮定位能力,對腫瘤生長有明顯的抑製作用,具有良好的RIT效果和潛在的臨床應用價值.
목적 탐토131I표기적항CD80단극륭항체4E5(131I-4E5)대하인림파류라서적치료효과.방법 채용Iodogen법진행4E5적131I표기,병대131I-4E5적면역활성급은정성진행분석;MTT법검측131I-4E5화4E5재체외대B림파류Raji세포적살상효응.경하류라서미정맥주입7.4 MBq(0.2 ml)적131I-4E5,72 h후처사하류라서,진행체내생물분포연구,계산각장기혹조직적방사성섭취(％ID/g).장하류라서안수궤수자표법분위3조,분별경미정맥주사131I-4E5、4E5급생리염수대조,관찰각조종류생장정황,계산급약후15 d적종류생장억제솔,연후처사하류라서,취종류조직행상규병리분석.실험수거채용단인소방차분석급량양본t검험분석.결과 131I-4E5적표기솔위(78.3±2.4)％,방화순위(95.7±1.8)％,비활도위579.4 GBq/g;131I-4E5여Raji세포적결합솔위(36.1±2.6)％;131I-4E5대Raji세포적살상작용정제량의뢰성,차이유통계학의의(F=33.882,P＜0.001),불동제량적131I-4E5대Raji세포적억제솔균고우4E5(t:3.986～5.515,균P＜0.05).생물분포결과현시,종류조직대131I-4E5유교고적섭취능력,종류/기육비치위6.05±1.20;여대조조비교,131I-4E5조화4E5조적종류생장균감만,기중131I-4E5적종류억제효과경위명현,급약후15d시적종류억제솔위71.69％.병리결과현시2조균가견종류세포배사,기중131I-4E5조종류세포배사경위명현.결론 131I-4E5재하림파류라서체내구유파향정위능력,대종류생장유명현적억제작용,구유량호적RIT효과화잠재적림상응용개치.
Objective To explore the therapeutic efficacy of 131I labeled anti-CD80 monoclonal antibody (4E5) in nude mice bearing human B-cell lymphoma.Methods The 4E5 was radiolabeled with 131I using the Iodogen method at room temperature,and the immune activity and stability of 131I-4E5 were analyzed.The lethal effects of 131I-4E5 and 4E5 against Raji cells were evaluated by MTT assay.Three tumorbearing nude mice were injected with 7.4 MBq of 131I-4E5 through tail vein,72 h later the mice were sacrificed and the ％ID/g was measured by calibrator and calculated.Fifteen tumor-bearing nude mice were randomly divided into 131I-4E5 group,4E5 group and normal saline control group according to different injections.The tumor inhibition rate was calculated 15 d post-injection,and then the mice were sacrificed to get tumor tissues for histopathological examination.One-way analysis of variance and two-sample t test were used to analyze the data.Results The labeling rate of 131I-4E5 was (78.3±2.4)％,the radiochemical purity was (95.7± 1.8)％ and specific activity was 579.4 GBq/g.The specific binding efficiency of 131I-4E5 with Raji cells was (36.1 ±2.6)％.131I-4E5 presented with a dose-dependent cytotoxicity against Raji cells.There were significant differences among the killing effects of different dosage groups (F=33.882,P＜0.001).Furthermore,131I-4E5 had higher growth inhibition rate on Raji cells than that of 4E5 (t:3.986-5.515,all P＜0.05).The biodistribution study showed that the tumor had high uptake of 131I-4E5,and the tumor/muscle ratio was 6.05± 1.20.The radioimmunotherapy results showed that the tumor growth suppression effect was more obvious in 131I-4E5 group and the tumor inhibition rate was 71.69％ on 15 d post-injection.The pathologic results showed necrosis in both 131I-4E5 group and 4E5 group,and the necrosis level was higher in 131I-4E5 group.Conclusion 131I-4E5 can target the tumor tissue and display an obvious antitumor effect in nude mice bearing human B-cell lymphoma.
